Sponsor: Alliance for Clinical Trials in Oncology
Sponsor Study ID: A032103
Study Title: MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
CTO #: 104042
NCT Number: NCT05987241
Phase: II/III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Bladder
Study Objectives: To compare the ctDNA clearance proportion at 12 weeks in patient enrolled in Cohort A treated with adjuvant nivolumab versus nivolumab + relatimab (phase 2 portion). To compare overall survival in patients enrolled in Cohort A treated with adjuvant nivolumab + relatlimab